PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

  • End date
    Jan 30, 2024
  • participants needed
  • sponsor
    Therapeutic Advances in Childhood Leukemia Consortium
Updated on 25 January 2021
graft versus host disease
lymphoid leukemia
total body irradiation
lymphoblastic lymphoma
ejection fraction
granulocyte colony stimulating factor
conjugated bilirubin
left ventricular fractional shortening


This is a phase 1/2 study of a drug called Ixazomib in combination with cytotoxic chemotherapy consisting of Vincristine, Dexamethasone, Asparaginase, and Doxorubicin (VXLD).


The phase 1 study is to determine the maximum tolerated dose (MTD) of the PO formulation, followed by a screening phase 2 study to investigate the efficacy of ixazomib in combination with chemotherapy in children with relapsed ALL and lymphoblastic lymphoma (LLy). The single arm, screening phase 2 design will allow us to use a minimal number of patients to obtain preliminary information about treatment efficacy. Discovering a safe and tolerable dose of ixazomib in a PO formulation and the preliminary efficacy data will significantly increase the possibility of ixazomib moving forward in frontline pediatric treatment protocols in both intense chemotherapy courses and maintenance courses.

Condition childhood ALL, Lymphocytic Leukemia, Acute, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Lymphoma, Childhood
Treatment Dexamethasone, vincristine, doxorubicin, Asparaginase, Ixazomib
Clinical Study IdentifierNCT03817320
SponsorTherapeutic Advances in Childhood Leukemia Consortium
Last Modified on25 January 2021


Yes No Not Sure

Inclusion Criteria

Age Patients must be 21 years of age at the time of enrollment
Phase 1 - Initial enrollment will be restricted to patients < 18 years of age until 9 such patients are enrolled
Phase 2 - Initial enrollment will be restricted to patients < 18 years of age until 6 such patients are enrolled
Diagnosis Patients must have a diagnosis of relapsed/refractory ALL or LLy with or without extramedullary disease (including CNS2 and CNS3). Patient with mixed phenotype ALL or mature B (Burkitt-like) leukemia are not eligible
Patients with ALL must have 5% blasts by morphology
Patients with LLy must have measurable disease documented by clinical, radiologic or histologic criteria
Performance Level Karnofsky 50% for patients > 16 years of age and Lansky 50% for patients 16 years of age
Prior Therapy A. Prior therapeutic attempts
Phase 1 - Any patients with relapsed/refractory ALL or LLy
Phase 2
B-cell ALL/LLy: all patients must have failed two or more therapeutic attempts
T-cell ALL/LLy: all patients must have failed one or more therapeutic attempts. B. Recent prior chemotherapy Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
Cytoreduction with hydroxyurea Hydroxyurea can be initiated and continued for up to 24 hours prior to the start of protocol therapy
Patients who relapsed while they are receiving cytotoxic therapy At least 14 days must have elapsed since the completion of the last dose of chemotherapy,except Intrathecal chemotherapy, and/or maintenance therapy such as vincristine, mercaptopurine, methotrexate or glucocorticoids. There is no waiting period for those relapsing on maintenance therapy. C. Hematopoietic stem cell transplant: Patients who have experienced their relapse after a HSCT are eligible, provided they have no evidence of acute or chronic Graft-versus-Host Disease (GVHD), are not receiving GVHD prophylaxis or treatment, and are at least 90 days post-transplant at the time of enrollment. D. Hematopoietic growth factors: It must have been at least 7 days since the completion of therapy with G-CSF or other growth factors at the time of enrollment. It must have been at least 14 days since the completion of therapy with pegfilgrastim (Neulasta). E. Biologic (anti-neoplastic agent): At least 7 days since the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair
Monoclonal antibodies: At least 3 half-lives of the antibody must have elapsed after the last dose of monoclonal antibody. (i.e., blinatumomab = 6 hours,44 inotuzumab = 37 days, rituximab = 66 days)
Immunotherapy: At least 30 days after the completion of any type of immunotherapy, e.g., tumor vaccines, CAR T cells
XRT: Craniospinal XRT is prohibited during protocol therapy. No washout period is necessary for radiation given to any extramedullary site other than CNS; 90 days must have elapsed if prior total body irradiation (TBI) or craniospinal XRT
Anthracyclines: Patients must have had a lifetime exposure of <400 mg/m2 of doxorubicin equivalents of anthracyclines
Proteasome inhibitors: Patients with a prior exposure to proteasome inhibitors (e.g., bortezomib, carfilzomib) are eligible as long as the patient demonstrated at least a partial response to a proteasome inhibitor with chemotherapy combination
Renal and hepatic function
Patients must have adequate renal and hepatic functions as indicated by the
following laboratory values
Adequate renal function defined as: Patient must have a calculated creatinine clearance or radioisotope GFR 70ml/min/1.73m2 OR a normal serum creatinine based on age/gender
Adequate Liver Function Defined as: Direct bilirubin 1.5 x upper limit of normal (ULN) for age or normal (except in the presence of Gilbert's syndrome), AND alanine transaminase (ALT) 5 x ULN for age. The hepatic requirements are waived for patients with known or suspected liver involvement by leukemia or lymphoma. This must be reviewed by and approved by the study chair or vice chair
Adequate Cardiac Function Defined as: Shortening fraction of more than or equal to 27% by echocardiogram, OR ejection fraction of equal to or more than 50% by radionuclide angiogram (MUGA)
Reproductive Function A. Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed within 2 weeks prior to enrollment
Female patients with infants must agree not to breastfeed their infants while on this study
Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of 6 months after study treatment
Informed Consent Patients and/or their parents or legal guardians must be capable of understanding the investigational nature, potential risks and benefits of the study. All patients and/or their parents or legal guardians must sign a written informed consent. Age appropriate assent will be obtained per institutional guidelines. To allow non-English speaking patients to participate in this study, bilingual health services will be provided in the appropriate language when feasible
All institutional, FDA, and OHRP requirements for human studies must be met

Exclusion Criteria

Patients will be excluded if they have isolated CNS or testicular disease
Patients will be excluded if they have grade 2 peripheral sensory or motor
neuropathy (defined by the Modified "Balis" Pediatric Scale of Pediatric
Neuropathies) at the time of enrollment (see section
Patients will be excluded if they have a known allergy or intolerance to any
of the drugs used in the study - except for PEG-asparaginase for which erwinia
asparaginase may be substituted
Patients will be excluded if they have a systemic fungal, bacterial, viral or
other infection that is exhibiting ongoing signs/symptoms related to the
infection without improvement despite appropriate antibiotics or other
treatment. The patient needs to be off pressors and have negative blood
cultures for 48 hours
Patients will be excluded if there is a plan to administer non-protocol
chemotherapy, radiation therapy, or immunotherapy during the study period
Patients will be excluded if they have significant concurrent disease
illness, psychiatric disorder or social issue that would compromise patient
safety or compliance with the protocol treatment or procedures, interfere with
consent, study participation, follow up, or interpretation of study results
Patients with DNA fragility syndromes (such as Fanconi anemia, Bloom syndrome)
are excluded
Patients will be excluded if they have had a lifetime exposure of 400 mg/m2
doxorubicin equivolents of anthracyclines (anthracycline equivalence to
doxorubicin conversion see appendix iv)
Concomitant medications Investigational drugs: Patients currently receiving
another investigational drug are not eligible
Anti-GVHD agents post transplant: patients who are receiving cyclosporine
tacrolimus or other agents to prevent graft-versus-host disease post
hematopoetic stem cell transplant are not eligible
CYP3A4 agents: patients who are currently receiving drugs that are strong
inducers of CYP3A4 are not eligible. Strong inducers of CYP3A4 should be
avoided from 14 days prior to enrollment to the end of the study. See appendix
ii for a list of agents which fall into this category
Patients with Ph+ALL and Ph-like ALL who are currently receiving TKI therapy
Infants or Patients with Down Syndrome will be excluded in phase 2 of the
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note